TY - JOUR
T1 - Effect of uterine luminal perfusion of PGF2α and PGE2 on uterine vasomotor response and PGF2α output in cyclic cattle
AU - Wolfenson, D.
AU - Thatcher, W. W.
AU - Bartol, F. F.
AU - Knickerbocker, J. J.
PY - 1987/8
Y1 - 1987/8
N2 - Six cyclic Holstein dairy cows were anesthetized on days 12-14 post-oestrus. Reproductive tract was exposed by midventral incision, and the ovarian (utero-ovarian) vein and facial artery cannulated. Oviduct was ligated, and a catheter (affluent) introduced into the tip of the uterine horn. The uterine horn was ligated above the uterine body, a second catheter (effluent) introduced into the uterine lumen, and an electromagnetic blood flow transducer placed around the uterine artery. On the day following surgery, the uterine horn was infused constantly for 9 h with PGF2α dissolved in PBS (0.7 ml/min, 177 ng/ml). During periods 1 and 3 (first 3 h and last 3 h, respectively) only PGF2α was perfused; during period 2 (between 3 h and 6 h) 101tgμg/ml of PGE2 were added to the perfusate together with PGF2α. Uterine venous and peripheral blood samples were collected simultaneously every 15 min, and uterine blood flow recorded continuously. Least-square means for PGF measured in uterine venous drainage for periods 1, 2 and 3 were 315 ± 26, 557 ± 24 and 511 ± 26 pg/ml, respectively (P < 0.05). Uterine blood flow values were 52 ± 5, 67 ± 4 and 61 ± 4 ml/min for periods 1, 2 and 3 (P < 0.08), respectively. Results do not support the hypothesis that the antiluteolytic effect of PGE2 is associated with a suppression of uterine PGF2α release into the circulation. Greater release of PGF to the circulation in period 2 (addition of PGE2) is probably the result of the vasodilatory effect of PGE2 on uterine endometrial vasculature.
AB - Six cyclic Holstein dairy cows were anesthetized on days 12-14 post-oestrus. Reproductive tract was exposed by midventral incision, and the ovarian (utero-ovarian) vein and facial artery cannulated. Oviduct was ligated, and a catheter (affluent) introduced into the tip of the uterine horn. The uterine horn was ligated above the uterine body, a second catheter (effluent) introduced into the uterine lumen, and an electromagnetic blood flow transducer placed around the uterine artery. On the day following surgery, the uterine horn was infused constantly for 9 h with PGF2α dissolved in PBS (0.7 ml/min, 177 ng/ml). During periods 1 and 3 (first 3 h and last 3 h, respectively) only PGF2α was perfused; during period 2 (between 3 h and 6 h) 101tgμg/ml of PGE2 were added to the perfusate together with PGF2α. Uterine venous and peripheral blood samples were collected simultaneously every 15 min, and uterine blood flow recorded continuously. Least-square means for PGF measured in uterine venous drainage for periods 1, 2 and 3 were 315 ± 26, 557 ± 24 and 511 ± 26 pg/ml, respectively (P < 0.05). Uterine blood flow values were 52 ± 5, 67 ± 4 and 61 ± 4 ml/min for periods 1, 2 and 3 (P < 0.08), respectively. Results do not support the hypothesis that the antiluteolytic effect of PGE2 is associated with a suppression of uterine PGF2α release into the circulation. Greater release of PGF to the circulation in period 2 (addition of PGE2) is probably the result of the vasodilatory effect of PGE2 on uterine endometrial vasculature.
UR - http://www.scopus.com/inward/record.url?scp=45949115825&partnerID=8YFLogxK
U2 - 10.1016/0378-4320(87)90090-X
DO - 10.1016/0378-4320(87)90090-X
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:45949115825
SN - 0378-4320
VL - 14
SP - 103
EP - 113
JO - Animal Reproduction Science
JF - Animal Reproduction Science
IS - 2
ER -